Agios PharmaceuticalsNASDAQ: AGIO

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.

Agios Pharmaceuticals said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study.

– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo –

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.

The mean of analysts' price targets for Agios Pharmaceuticals (AGIO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Agios (AGIO) releases a combination of earnings results for the first quarter of 2024. While sales fall short of expectations, revenue from its only available drug, Pyrukynd, increases compared to previous quarters and the same time last year.

Agios Pharmaceuticals (AGIO) reported a quarterly loss of $1.45 per share, beating the Zacks Consensus Estimate of a loss of $1.64. This is an improvement from the loss of $1.47 per share in the same quarter last year.

Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.